Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ICCC | US
0.04
0.49%
Healthcare
Biotechnology
30/06/2024
13/04/2026
7.11
7.25
7.30
7.10
ImmuCell Corporation an animal health company develops manufactures and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense a passive antibody product for the treatment of E. coli coronavirus and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk as well as to determine which quarter of the udder is mastitic; and Dual-Force First Defense including a whey protein concentrate for the nutritional and feed supplement markets. In addition it is involved in developing Re-Tain a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland Maine.
View LessPositive Momentum
Strength based on increasing price with high volume
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
High Short-term Volatility
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
70.9%1 month
57.3%3 months
48.6%6 months
53.3%-
-
1.23
0.68
0.38
-21.19
1.87
-
-633.70K
55.69M
55.69M
-
-25.34
-63.40
54.90
-16.10
0.20
0.18
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.28
Range1M
1.50
Range3M
1.75
Rel. volume
1.92
Price X volume
269.75K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| QNCX | QNCX | Biotechnology | 1.41 | 61.02M | 3.45% | n/a | 30.62% |
| Equillium Inc | EQ | Biotechnology | 1.7 | 60.22M | -5.56% | n/a | 2.71% |
| VANI | VANI | Biotechnology | 1.05 | 58.02M | 0.96% | n/a | 84.10% |
| CDIO | CDIO | Biotechnology | 1.88 | 57.53M | 2.73% | n/a | 28.31% |
| PEPG | PEPG | Biotechnology | 1.69 | 55.08M | 3.05% | n/a | 12.52% |
| THL Credit Inc. 6.75% Notes du | TCRX | Biotechnology | 1.02 | 54.03M | -2.86% | n/a | 35.68% |
| TPST | TPST | Biotechnology | 2.14 | 53.94M | 4.39% | n/a | 119.58% |
| Sangamo Therapeutics Inc | SGMO | Biotechnology | 0.257 | 53.51M | 2.31% | n/a | 122.82% |
| OKYO Pharma Limited | OKYO | Biotechnology | 1.53 | 51.77M | 1.32% | n/a | -107.88% |
| Clene Nanomedicine Inc | CLNN | Biotechnology | 6.48 | 51.59M | 6.06% | n/a | -6472.02% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 10.4 | 15.84M | -11.56% | n/a | 204.46% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.8799 | 12.86M | -18.53% | 0.03 | 16.03% |
| REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 0.6 | 11.59M | -0.17% | n/a | 58.43% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.33 | 3.40M | -0.75% | n/a | 17.32% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.2276 | 2.17M | -10.25% | n/a | 19.98% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.07 | 1.14M | -0.96% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -21.19 | 0.53 | Cheaper |
| Ent. to Revenue | 1.87 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.23 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 48.57 | 72.80 | Lower Risk |
| Debt to Equity | 0.68 | -1.23 | Expensive |
| Debt to Assets | 0.38 | 0.25 | Expensive |
| Market Cap | 55.69M | 3.66B | Emerging |